Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.co

National Stock Exchange of India Ltd. (Scrip Code:

BSE Limited (Scrip Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

Please find enclosed a Press Release on "Dr.

Reddy's issues voluntary nationwide recall of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg due to Sub-potency".

This is for your information and records.

For Dr. Reddy's Laboratories Limited

Company Secretary, Compliance Officer & Head-CSR

issues voluntary nationwide recall of

Sapropterin Dihydrochloride Powder for Oral Solution 100 mg

FOR IMMEDIATE RELEASE Hyderabad India and Princeton,

NJ, US; April 23, 2024 - Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its

subsidiaries together referred to as "Dr. Reddy's"), today announced that it is voluntarily recalling six (6) lots of Sapropterin

Dihydrochloride Powder for Oral Solution 100 mg to the consumer level due to powder discoloration in some packets leading to decreased

potency. The issue was discovered during an accelerated stability test in addition to customer complaints.

Risk Statement: Reduced efficacy of the product

would result in elevated Phenylalaninemia (Phe) levels in patients. Chronically elevated Phe levels in infants and children are likely

to cause permanent neurocognitive deficits, including permanent and irreversible intellectual disability, developmental delay, and seizures.

Furthermore, elevated Phe levels during pregnancy, especially in early gestation, are associated with microcephaly and congenital heart

Dr. Reddy's Laboratories Inc. has not received

any reports of adverse events related to this recall to date.

The product is indicated to reduce blood phenylalanine

(Phe) levels in adult and pediatric patients one month of age and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin-(BH4-)

responsive Phenylketonuria (PKU) and is packaged in individual packets, 30 per carton. The affected Sapropterin Dihydrochloride Powder

for Oral Solution 100mg lots include the following:

Sapropterin Dihydrochloride Powder for Oral Solution

100 mg was distributed nationwide to wholesalers/retailers.

Reddy's Laboratories Inc. is notifying its distributors and customers by recall notification letters and is arranging for returns

of all recalled products. Anyone with an existing inventory of the product

being recalled should examine the product and quarantine any of the recalled lots immediately. Consumers who have Sapropterin Dihydrochloride

Powder for Oral Solution 100 mg which is being recalled should contact their physician before stopping use of the product. Consumers who

have Sapropterin Dihydrochloride Powder for Oral Solution 100 mg which is being recalled should return it to their place of purchase.

Consumers with questions regarding this recall can

contact Dr. Reddy's Laboratories Inc. by calling 866-733-3952 during office hours from 9 a.m. to 5 p.m. (EST) Monday through Friday.

Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or

using this drug product.

Adverse reactions or quality problems experienced

with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by

This recall is being conducted with the knowledge

of the U.S. Food and Drug Administration.

Please click here to see the full prescribing information

for Sapropterin Dihydrochloride Powder for Oral Solution 100 mg.

About Dr. Reddy's: Dr. Reddy's

Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is a global pharmaceutical company headquartered in Hyderabad,

India. Established in 1984, we are committed to providing access to affordable and innovative medicines. Driven by our purpose of Good

Health Can't Wait', we offer a portfolio of products and services including APIs, generics, branded generics, biosimilars

and OTC. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.

Our major markets include - USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep

science that has led to several industry firsts, we continue to plan ahead and invest in businesses of the future. As an early adopter

of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high

in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com.

Disclaimer: This press release may include statements

of future expectations and other forward-looking statements that are based on the management's current views and assumptions and

involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those

expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may",

"will", "should", "expects", "plans", "intends", "anticipates", "believes",

"estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking

statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general

economic conditions such as performance of financial markets, credit defaults , currency exchange rates, interest rates, persistency levels

and frequency / severity of insured loss events, (ii) mortality and morbidity levels and trends, (iii) changing levels of competition

and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the

impact of acquisitions or reorganization, including related integration issues, and (vi) the susceptibility of our industry and the markets

addressed by our, and our customers', products and services to economic downturns as a result of natural disasters, epidemics, pandemics

or other widespread illness, including coronavirus (or COVID-19), and (vii) other risks and uncertainties identified in our public filings

with the Securities and Exchange Commission, including those listed under the "Risk Factors" and "Forward-Looking Statements"

sections of our Annual Report on Form 20-F for the year ended March 31, 2023. The company assumes no obligation to update any information